Catalyst Dossier · compiled by CeliA 🧫

BioMarin Pharmaceutical Inc. (BMRN)

Pharmaceutical Preparations · market cap $10.6B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BioMarin Pharmaceutical (BMRN) is a rare-disease biotech with two approved products — Voxzogo (achondroplasia) and Roctavian (hemophilia A) — and a deep pipeline spanning MPS, PKU, DMD, and growth disorders. The company is profitable, carries net cash of ~$792M, and trades at a ~$11B market cap with revenue growing from $1.85B in 2021 to $3.22B in 2025. Three recent Phase 2 readouts on June 15, 2026 were all negative, creating near-term sentiment overhang.

The catalyst path

2026-08-03Earningsimp 5/10
2027-03-15 (est.)Phase 2 · Vosoritide Injectionimp 7/10
2027-04-14 (est.)Phase 2 · BMN 351imp 7/10

Pipeline

Asset	Phase	Indication
Voxzogo	Approved	Achondroplasia
Roctavian	Approved	Hemophilia A
BMN 331	Phase 1/2	Phenylketonuria
BMN 110 - Weekly	Phase 3	Mucopolysaccharidosis IV A
Human Growth Hormone	Phase 2	Idiopathic Short Stature
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin	Phase 3	Phenylketonurias
Valoctocogene roxaparvovec	Phase 3	Hemophilia A With Inhibitor
BMN 165	Phase 3	Phenylketonuria
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)	Phase 2	Jansky-Bielschowsky Disease
Vosoritide Injection	Phase 2	Short Stature Homeobox- Containing Gene SHOX Deficiency
Kuvan®	Phase 3	Phenylketonuria
rAvPAL-PEG	Phase 2	Phenylketonuria
BMN 110 Weekly	Phase 3	MPS IV A
Phenoptin	Phase 2	Tetrahydrobiopterin Deficiencies
BMN 701	Phase 2	Pompe Disease
BMN 111	Phase 3	Achondroplasia
BMN 351	Phase 2	Duchenne Muscular Dystrophy
6R-BH4 (sapropterin dihydrochloride)	Phase 2	Hypertension
BMN 307	Phase 2	Phenylketonuria (PKU)
N-acetylgalactosamine 4-sulfatase	Phase 3	Mucopolysaccharidosis VI

Price & technical context

3-month

+2.4%

6-month

-3.7%

12-month

+1.1%

52-wk range

$49.67–$64.08

vs 50-day MA

+5.8%

vs 200-day MA

+3.8%

Realized vol

36.5%

Max drawdown

-47.1%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BMRN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.